Liprolog (insulin lispro)
- Region
- 🇪🇺 EU
- Active substance
- insulin lispro
- Company
- Eli Lilly and Company Limited
- Status
- Withdrawn
- Therapeutic area
- Diabetes Mellitus
- EU approval
- Wed 07 May 1997
- Application
- EMEA/H/C/000143
- ATC
- A10AB04
- Official record
- www.ema.europa.eu
Indication
For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilization of diabetes mellitus. Liprolog is a short acting insulin and may be used in conjunction with a longer acting human insulin. Liprolog is indicated for preprandial administration.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Bysumlog Authorised · Sandoz GmbH
- 🇪🇺 Lyumjev (previously Liumjev) Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Humalog Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Insulin lispro Sanofi Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Liprolog Authorised · Eli Lilly Nederland B.V.
Follow Liprolog
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.